HAHassan Argani

Hassan Argani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hassan Argani has a total of 75 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Therapeutic Apheresis in Pediatric Renal Transplant Recipients

    by Hassan Argani

    Clear guidelines for therapeutic apheresis in children after renal transplant do not exist. This article reviews the current experiences with therapeutic apheresis in pediatric transplant recipients. The ideal characteristics of removable substances should have all of the following criteria for an effective therapeutic apheresis: large molecular weight (>15 kDa), prolonged half-life, rapid elimination from the plasma, high intravascular distribution, and low turnover rate. Among these molecules, immunoglobulin M is ~75% intravascular; thus, only 1 or 2 therapeutic apheresis procedures are needed to reduce immunoglobulin M levels efficiently. In contrast, immunoglobulin G is distributed 45% intravascularly and returns to ~60% of preapheresis level within 48 hours; thus, the regimen involves 5 procedures and immunosuppressive therapy is crucial to reduce immunoglobulin G levels. Therapeutic apheresis can also remove cytokines. Immunomodulatory effects of therapeutic apheresis do not only remove unwanted substances but involve other important mechanisms, including increased T-regulatory cells compared with T-effector cells. Many modalities of therapeutic apheresis are used for pediatric transplant recipients, including plasmapheresis, double filtration plasmapheresis, photopheresis, lipopheresis, and immunoadsorption, which is the most effective but has a high cost. Therapeutic apheresis in pediatric transplant recipients is effective for posttransplant nephrotic syndrome (mainly focal segmental glomerulosclerosis). Therapeutic apheresis has also resulted in partial or complete remission for 66% of patients with atypical hemolytic uremic syndrome and 75% response rate for chronic antibody-mediated rejection. However, therapeutic apheresis should be accompanied by other immunosuppressive drugs to prevent rebound phenomena. Potential complications of therapeutic apheresis in pediatric transplant recipients include fluid and electrolyte imbalances, infection, bleeding, and reactions to replacement fluids during therapeutic apheresis. However, therapeutic apheresis (combined with immunosuppression) is an effective tool in most pediatric renal transplant recipients for management of antibody-mediated rejection, focal segmental glomerulosclerosis, and atypical hemolytic uremic syndrome.

  • Second and Third Kidney Transplants

    by Hassan Argani

    Renal transplant is the best procedure for patients with end-stage renal disease. Although an ideal kidney transplant should survive for the lifetime of each recipient, there may be a need for a second, third, or even a fourth retransplant. The outcomes of these kidney allografts, surgical approaches, immunology issues, and drug therapies warrant greater focus. Pediatric kidney retransplant is even more important because these patients are more immunologically responsive to donor antigens and because they need longer allograft survival. Although kidney retransplant provides a survival advantage for patients who would otherwise remain on the wait list and/or hemodialysis, careful patient selection is crucial for second, third, and fourth renal transplants. Despite the shortage of donor organs, outcomes, manageable complications, and economic considerations support earlier kidney retransplants rather than delayed retransplants. Preoperative vascular imaging, appropriate induction therapy, regular monitoring of renal function, and regular surveillance for malignancy and infection are more important in the retransplanted kidneys than in cases of first kidney transplants. The lack of robust data on optimal clinical management of these retransplant recipients has contributed to substantial variations in clinical practice among different centers. In this review, we discuss medical and surgical approaches in the cases of second and third kidney transplants.


  • Open Access

    Effect of Lower- versus Higher-Intensity Isometric Handgrip Training in Adults with Hypertension: A Randomized Controlled Trial

    by Mohsen Javidi, Sajad Ahmadizad, Hassan Argani, Abdolrahman Najafi, Khosrow Ebrahim, Narges Salehi, Yasaman Javidi, Linda S. Pescatello, Alireza Jowhari, Daniel A. Hackett

    This study compared the effects of lower- versus higher-intensity isometric handgrip exercise on resting blood pressure (BP) and associated clinical markers in adults with hypertension. Thirty-nine males were randomly assigned to one of three groups, including isometric handgrip at 60% maximal voluntary contraction (IHG-60), isometric handgrip at 30% IHG-30, or a control group (CON) that had been instructed to continue with their current activities of daily living. The volume was equated between the exercise groups, with IHG-60 performing 8 × 30-s contractions and IHG-30 performing 4 × 2-min contractions. Training was performed three times per week for 8 weeks. Resting BP (median [IQR]), flow-mediated dilation, heart rate variability, and serum markers of inflammation and oxidative stress were measured pre- and post-intervention. Systolic BP was significantly reduced for IHG-60 (−15.5 mmHg [−18.75, −7.25]) and IHG-30 (−5.0 mmHg [−7.5, −3.5]) compared to CON (p < 0.01), but no differences were observed between both the exercise groups. A greater reduction in diastolic BP was observed for IHG-60 (−5.0 mmHg [−6.0, −4.25] compared to IHG-30 (−2.0 mmHg [−2.5, −2.0], p = 0.042), and for both exercise groups compared to CON (p < 0.05). Flow-mediated dilation increased for both exercise groups versus CON (p < 0.001). IHG-30 had greater reductions in interleukin-6 and tumor necrosis factor-α compared to the other groups (p < 0.05) and CON (p = 0.018), respectively. There was a reduction in Endothelin-1 for IHG-60 compared to CON (p = 0.018). Both the lower- and higher-intensity IHG training appear to be associated with reductions in resting BP and improvements in clinical markers of inflammation and oxidative stress.


  • Expanded Criteria Donors

    by Hassan Argani

    The expanded criteria donor is any donor over the age of 60 years or a donor over the age of 50 years with 2 of the following 3 items: (1) history of high blood pressure, (2) serum creatinine >= 1.5 mg/dL, and (3) death due to stroke. To accept an expanded criteria donor kidney may significantly decrease the amount of time a person waits for transplant but requires written informed consent from the recipient. Although expanded criteria donor kidneys have predictably shorter outcomes than standard criteria donors, the exact risk is unknown. At 5 years follow-up, 50% of expanded criteria donor kidneys are still working. Regardless of donor status of these kidneys as expanded criteria or standard criteria, the transplant recipients have higher survival rates compared with candidates who remain on the wait list. The success rate may be increased when a perfusion pump is used to preserve the kidneys. Sometimes the function of a single kidney from an expanded criteria donor is deemed insufficient. In this situation, a pair of marginally functioning kidneys may be transplanted as a dual-kidney transplant. This dual transplant option offers acceptable outcomes as good as a single-kidney transplant with normal function and can effectively address the shortage of donor organs. The use of a perfusion pump allows the clinician to decide whether or not to use a particular expanded criteria donor kidney. Expanded criteria donors may be justified by meticulous selection of each donor for recipients, along with more sophisticated surgical techniques to maximize the kidney donor pool.


  • Donation After Cardiac Death in Children

    by Hassan Argani

    The wait list for organ transplant exceeds the rate of organ donation, especially in children. The solid-organ transplant rate has remained stable over time, despite increased demand. Although donation after cardiac death has helped to expand the donor organ pool for the adult population, this option remains scarce for children in need of transplant. Because long-term graft survival is more important in the pediatric group than in adults, we should reconsider the common notion that donation after cardiac death is inferior to donation after brain death. Herein, we review the literature to extract and analyze data regarding donation after cardiac death for solid-organ transplant in children.


  • Genome Engineering for Stem Cell Transplantation

    by Hassan Argani

    To avoid the ethical issues of embryonic stem cells, genome engineering has focused on inducible pluripotent stem cells, which can develop into all 3 germ layers. The ability to detect methylation patterns in these cells allows research into pluripotency markers. The recently developed CRISPR system has allowed widespread application of genome engineering techniques. The CRISPR-Cas9 system, a potent system for genome editing, can be used for gene knockout or knock-in genome manipulations through substitution of a target genetic sequence with a desired donor sequence. Two types of genome engineering can be initiated: homologous or non homologous DNA repair by the Cas9 nuclease. Delivery of the CRISPR-Cas9 and target donor vectors in human pluripotent stem cells can be accomplished via viral and nonviral delivery methods. Nonviral delivery includes lipid-mediated transfection and electroporation. It has become the most common and efficient in vitro delivery method for human pluripotent stem cells. The CRISPR-Cas9 system can be combined with inducible pluripotent stem cells to generate single or multiple gene knockouts, correct mutations, or insert reporter transgenes. Knockouts can also be utilized to investigate epigenetic roles and targets, such as investigation of DNA methylation. CRISPR could be combined with human pluripotent stem cells to explore genetic determinants of lineage choice, differentiation, and stem cell fate, allowing investigators to study how various genes or noncoding elements contribute to specific processes and pathways. The CRISPR-Cas9 system can also be used to create null or nucleasedead Cas9, which has no enzymatic activity but has been utilized through fusion with other functional protein domains. In conclusion, RNA-guided genome targeting will have broad implications for synthetic biology, direct perturbation of gene networks, and targeted ex vivo and in vivo gene therapy.


  • Soluble Tumor Necrosis Factor Like Weak Inducer of Apoptosis and Vitamin D in Hemodialysis Patients: Relation to Carotid Intima-Media Thickness

    by Farahnaz Askarian, Amir Ghorbanihaghjo, Hassan Argani, Davoud Sanajou, Nima Nasehi, Roya Askarian, Ravan Ahmadi, Nadereh Rahtchizadeh

    Cardiovascular disease, as the leading cause of patient death with chronic kidney disease, could be predicted by carotid atherosclerosis. The aim of the present study was to evaluate a possible relationship between serum soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) and Vitamin D levels with mean right/left carotid intima-media thickness (cIMT), in the hemodialysis (HD) patients. In this cross-sectional study, serums were obtained from 50 stable chronic HD patients and 39 healthy controls. The serum levels of sTWEAK, Vitamin D, intact parathyroid hormone (iPTH) in both groups, and cIMT were determined in HD patients by standard methods. Serum levels of sTWEAK were higher [808.8 (521.6-5032.4) pg/ml vs. 664.4 (487.4-2955.8) pg/ml (p = 0.006)] and Vitamin D levels were lower [13.4 (2.5-153) ng/ml vs. 27.8 (18.4-59.0) ng/ml (p = 0.001)] in the hemodialysis patients than in the healthy control. No important correlation was found between sTWEAK Vitamin D levels (r = 0.010/p = 0.946), and mean right(r = -0.194/p = 0.178) and left (r = 0.061/p = 0.673) cIMT in the HD patients. Our study shows that sTWEAK levels are elevated in HD patients. This elevation has no association with the cIMT.

  • Open Access

    Effect of Zinc Supplementation on Blood Pressure and Complete Blood Count in Hemodialysis Patients

    by Mohammad Mazani, Hassan Argani, Nadereh Rashtchizadeh, Shokofeh Banaei, Babak Kazemi Arbat, Lotfollah Rezagholizadeh

    Objectives: Zinc is an important trace element in human nutrition and its deficiency is a worldwide problem. Zinc deficiency incidence is predominantly high in many diseases such as ESRD (End Stage Renal Disease) patients undertaking hemodialysis (HD). Beside, hypertension and cardiac output, is a predictor of cardiovascular mortality in HD patients. This study investigated the effects of zinc supplementation on blood pressure (BP) and complete blood count (CBC) in HD patients. Materials and Methods: In a randomized, double-blind, and placebo-controlled trial, Sixty-five HD patients were randomly divided into two groups. Patients in group I and group II received placebo and Zn supplementation (100 mg/day) respectively for two months. After withdrawing for the duration of the next two months, the study was continued as a crossover design for another two months (group I and II received zinc supplementation and placebo, respectively). Systolic and diastolic BP, cardiac ejection fraction (EF), and CBC were measured at the 0th, 60th, 120th, and 180th days. Statistical analyses were performed using SPSS software. Results: Zinc supplementation resulted in a significant increase in the mean red blood cell (RBC), Hematocrit (Hct), whereas a significant decrease was seen in systolic and diastolic BP. Changes observed in the placebo group were not significant. Conclusion: Zinc supplementation for two months improved the systolic and diastolic BP, RBC, and Hct in HD patients.


    • 1 April 2015
      • Vol. 65  (4) , 354-7

    Association between hepcidin, haemoglobin level and iron status in stage 4 chronic kidney disease patients with anaemia.

    by Reza Alipanah-Moghadam, Ali Nemati, Firouz Amani, Amir Ghorbanihaghjo, Hassan Argani, Bahman Bashardoust

    To explore the probable association of serum hepcidin and haemoglobin levels with iron and inflammation statuses in patients of chronic kidney disease stage 4 with anaemia. The cross-sectional study was conducted at Tabriz University of Medical Sciences, Iran, from March 2011 to October 2012, and comprised patients of chronic kidney disease stage 4 with anaemia. Serum biochemical factors as well as hepcidin, ferritin, interleukin 6, high sensitivity C-reactive protein and iron levels were measured using standard methods. Statistical correlations were established using regression analysis and Pearson's correlation coefficient. There were 40 patients among whom 15(37.5%) were males and 25(62.5%) were females with an overall mean age of 55.68±14.4 years. There was a significant inverse relationship between hepcidin and haemoglobin levels (p<0.05). There were significant correlations between hepcidin with iron status, nutritional and inflammatory markers such as ferritin, Total iron binding capacity, albumin and interleukin 6 (p<0.05 each). Hepcidin had negative correlation with haemoglobin level in stage 4 chronic kidney disease patients with adequate iron stores, which could be effective in the development of anaemia in such patients.

    • 1 September 2014
      • Vol. 8  (5) , 394-400

    Relationship between vitamin D receptor gene FokI and ApaI polymorphisms and serum levels of fetuin-A, vitamin D, and parathyroid hormone in patients on hemodialysis.

    by Amir Ghorbanihaghjo, Hassan Argani, Nasar Samadi, Shahnam Valizadeh, Jamal Halajzadeh, Bahman Yousefi, Nadereh Rashtchizadeh

    Low fetuin-A and 1,25-hydroxyvitamin D3 (vitamin D) levels accompanied with high intact parathyroid hormone (PTH) contents are associated with cardiovascular disease in dialysis patients. The aim of present study was to evaluate the relationship between vitamin D receptor (VDR) gene FokI and ApaI polymorphisms with serum levels of fetuin-A, vitamin D, and intact PTH in hemodialysis patients. Serum was obtained from 46 stable chronic hemodialysis patients and 43 healthy controls. Serum levels of intact PTH, fetuin-A, vitamin D, calcium, and phosphorus were measured. Genotyping of the VDR gene was performed using standard methods. Serum fetuin-A and vitamin D levels were significantly lower, whereas serum levels of PTH, calcium, and Phosphorus were higher in the hemodialysis patients than in the healthy controls. The FokI genotypes were more frequent in the hemodialysis patients than the control group (P = .004). With respect to FokI genotypes, intact PTH level was higher among the hemodialysis patients compared to the controls (P = .02). In contrast, vitamin D level was lower in the hemodialysis patients with ApaI genotypes compared to the control group (P = .04). Our study shows that increased serum level of PTH and decreased fetuin-A and vitamin D levels may increase susceptibility of atherosclerosis in patients with hemodialysis through VDR gene FokI and ApaI polymorphisms.